| Patient Perceptions of Using the OmniPod System Compared with Conventional Insulin Pumps in Young Adults with Type 1 Diabetes. | |
| | |
MedLine Citation:
|
PMID: 22283640 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Aims: This study evaluated treatment satisfaction, comfort, and function using the wireless OmniPod™ Insulin Management System (Insulet Corp., Bedford, MA) compared with conventional (infusion set) insulin pumps in young adults with type 1 diabetes. Research Design and Methods: Twenty-nine patients (age, 24.0±5.1 years; diabetes duration, 12.1±5.7 years; insulin pump duration, 6.4±3.1 years; glycated hemoglobin [HbA1c], 8.6±0.7%) participated in a randomized, two-arm open crossover study comparing two consecutive 12-week periods of continuous subcutaneous insulin infusion (CSII): one period using the OmniPod system and the other period using conventional CSII. The main outcome measures were treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire), user evaluation (OmniPod System User Evaluation Questionnaire), and HbA1c levels. Results: Treatment satisfaction at baseline was high, with a mean score of 28.6±4.6 (maximal score, 36) and no significant difference between the two randomized groups. Upon completion of the study period 43% "would switch to OmniPod," 36% were "undecided," and 21% "would not switch pumps." Seventy-six percent preferred the OmniPod automated cannula insertion system, and 56% reported that OmniPod fit better into their lifestyle than conventional CSII. HbA1c levels significantly decreased with both OmniPod and conventional CSII (7.9±0.9% vs. 8.8±0.7% and 8.2±0.9% vs. 8.5±0.5%, respectively; P<0.001 for both groups) after completion of the first treatment arm. The decrease in HbA1c was more marked in the OmniPod group (P=0.044), without additional improvement at the end of the study in either group. Conclusions: The OmniPod system was well received by young adults with type 1 diabetes experienced with conventional CSII. |
| | |
Authors:
|
Yael Lebenthal; Liora Lazar; Hadassa Benzaquen; Shlomit Shalitin; Moshe Phillip |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-27 |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: - ISSN: 1557-8593 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1 The Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel , Petach Tikva, Israel . |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Does the Timing of Insulin Pump Therapy Initiation After Type 1 Diabetes Onset Have an Impact on Gly...
Next Document: Complementary and Synergistic Roles in Enzyme-Catalyzed Regioselective and Complete Hydrolytic Depro...